Genetically modified organisms are the key step for innovative medicines. The innovative drugs in the 21*' century will be in the majority of proteins, nucleic acids and their combinations. The critical issues in case of biopharmaceuticals are quality and reproducibility of production. These aspects are evident in biosimilars (generics) and protection of intellectual property rights.
Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.
Feb 18, 2020
Jun 3, 2019
|GMO, czyli innowacyjne biotechnologie w medycynie XXI w.||Feb 18, 2020|
Twardowska, Aleksandra Twardowski, Tomasz
Lubiatowska-Krysiak, Eliza Twardowski, Tomasz
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Schmitt, Claudia Stencel, Dariusz